 | • レポートコード：QYR2104Z4089 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、神経内分泌がんのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（化学療法、ソマトスタチン類似体、標的療法）、用途別市場規模（病院、診療所、腫瘍学センター、外来手術センター）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・神経内分泌がんの市場動向 ・企業の競争状況、市場シェア ・神経内分泌がんの種類別市場規模（化学療法、ソマトスタチン類似体、標的療法） ・神経内分泌がんの用途別市場規模（病院、診療所、腫瘍学センター、外来手術センター） ・神経内分泌がんの北米市場規模2016-2027（アメリカ、カナダ） ・神経内分泌がんのヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・神経内分泌がんのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・神経内分泌がんの中南米市場規模2016-2027（メキシコ、ブラジル） ・神経内分泌がんの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Pfizer、Novartis、Chiasma、Ipsen、Abbvie、Valeant、Jubilant、Teva、F.Hoffmann-La Roche、Advanced Accelerator、Mateon、Lexicon） ・結論 |
Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.
The somatostatin analogs segment by treatment type is expected to witness high traction in the coming years.
Market Analysis and Insights: Global Neuroendocrine Carcinoma Market
The global Neuroendocrine Carcinoma market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neuroendocrine Carcinoma market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neuroendocrine Carcinoma market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neuroendocrine Carcinoma market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neuroendocrine Carcinoma market.
Global Neuroendocrine Carcinoma Scope and Market Size
Neuroendocrine Carcinoma market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neuroendocrine Carcinoma market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Chemotherapy
Somatostatin Analogs
Targeted Therapy
Segment by Application
Hospital
Clinics
Oncology Centres
Ambulatory Surgery Centres
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Pfizer
Novartis
Chiasma
Ipsen
Abbvie
Valeant
Jubilant
Teva
F.Hoffmann-La Roche
Ipsen
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuroendocrine Carcinoma Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Chemotherapy
1.2.3 Somatostatin Analogs
1.2.4 Targeted Therapy
1.3 Market by Application
1.3.1 Global Neuroendocrine Carcinoma Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Oncology Centres
1.3.5 Ambulatory Surgery Centres
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neuroendocrine Carcinoma Market Perspective (2016-2027)
2.2 Neuroendocrine Carcinoma Growth Trends by Regions
2.2.1 Neuroendocrine Carcinoma Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neuroendocrine Carcinoma Historic Market Share by Regions (2016-2021)
2.2.3 Neuroendocrine Carcinoma Forecasted Market Size by Regions (2022-2027)
2.3 Neuroendocrine Carcinoma Industry Dynamic
2.3.1 Neuroendocrine Carcinoma Market Trends
2.3.2 Neuroendocrine Carcinoma Market Drivers
2.3.3 Neuroendocrine Carcinoma Market Challenges
2.3.4 Neuroendocrine Carcinoma Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuroendocrine Carcinoma Players by Revenue
3.1.1 Global Top Neuroendocrine Carcinoma Players by Revenue (2016-2021)
3.1.2 Global Neuroendocrine Carcinoma Revenue Market Share by Players (2016-2021)
3.2 Global Neuroendocrine Carcinoma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neuroendocrine Carcinoma Revenue
3.4 Global Neuroendocrine Carcinoma Market Concentration Ratio
3.4.1 Global Neuroendocrine Carcinoma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Revenue in 2020
3.5 Neuroendocrine Carcinoma Key Players Head office and Area Served
3.6 Key Players Neuroendocrine Carcinoma Product Solution and Service
3.7 Date of Enter into Neuroendocrine Carcinoma Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuroendocrine Carcinoma Breakdown Data by Type
4.1 Global Neuroendocrine Carcinoma Historic Market Size by Type (2016-2021)
4.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Type (2022-2027)
5 Neuroendocrine Carcinoma Breakdown Data by Application
5.1 Global Neuroendocrine Carcinoma Historic Market Size by Application (2016-2021)
5.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Neuroendocrine Carcinoma Market Size (2016-2027)
6.2 North America Neuroendocrine Carcinoma Market Size by Type
6.2.1 North America Neuroendocrine Carcinoma Market Size by Type (2016-2021)
6.2.2 North America Neuroendocrine Carcinoma Market Size by Type (2022-2027)
6.2.3 North America Neuroendocrine Carcinoma Market Size by Type (2016-2027)
6.3 North America Neuroendocrine Carcinoma Market Size by Application
6.3.1 North America Neuroendocrine Carcinoma Market Size by Application (2016-2021)
6.3.2 North America Neuroendocrine Carcinoma Market Size by Application (2022-2027)
6.3.3 North America Neuroendocrine Carcinoma Market Size by Application (2016-2027)
6.4 North America Neuroendocrine Carcinoma Market Size by Country
6.4.1 North America Neuroendocrine Carcinoma Market Size by Country (2016-2021)
6.4.2 North America Neuroendocrine Carcinoma Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Neuroendocrine Carcinoma Market Size (2016-2027)
7.2 Europe Neuroendocrine Carcinoma Market Size by Type
7.2.1 Europe Neuroendocrine Carcinoma Market Size by Type (2016-2021)
7.2.2 Europe Neuroendocrine Carcinoma Market Size by Type (2022-2027)
7.2.3 Europe Neuroendocrine Carcinoma Market Size by Type (2016-2027)
7.3 Europe Neuroendocrine Carcinoma Market Size by Application
7.3.1 Europe Neuroendocrine Carcinoma Market Size by Application (2016-2021)
7.3.2 Europe Neuroendocrine Carcinoma Market Size by Application (2022-2027)
7.3.3 Europe Neuroendocrine Carcinoma Market Size by Application (2016-2027)
7.4 Europe Neuroendocrine Carcinoma Market Size by Country
7.4.1 Europe Neuroendocrine Carcinoma Market Size by Country (2016-2021)
7.4.2 Europe Neuroendocrine Carcinoma Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Neuroendocrine Carcinoma Market Size (2016-2027)
8.2 Asia-Pacific Neuroendocrine Carcinoma Market Size by Type
8.2.1 Asia-Pacific Neuroendocrine Carcinoma Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neuroendocrine Carcinoma Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neuroendocrine Carcinoma Market Size by Type (2016-2027)
8.3 Asia-Pacific Neuroendocrine Carcinoma Market Size by Application
8.3.1 Asia-Pacific Neuroendocrine Carcinoma Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neuroendocrine Carcinoma Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neuroendocrine Carcinoma Market Size by Application (2016-2027)
8.4 Asia-Pacific Neuroendocrine Carcinoma Market Size by Region
8.4.1 Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neuroendocrine Carcinoma Market Size (2016-2027)
9.2 Latin America Neuroendocrine Carcinoma Market Size by Type
9.2.1 Latin America Neuroendocrine Carcinoma Market Size by Type (2016-2021)
9.2.2 Latin America Neuroendocrine Carcinoma Market Size by Type (2022-2027)
9.2.3 Latin America Neuroendocrine Carcinoma Market Size by Type (2016-2027)
9.3 Latin America Neuroendocrine Carcinoma Market Size by Application
9.3.1 Latin America Neuroendocrine Carcinoma Market Size by Application (2016-2021)
9.3.2 Latin America Neuroendocrine Carcinoma Market Size by Application (2022-2027)
9.3.3 Latin America Neuroendocrine Carcinoma Market Size by Application (2016-2027)
9.4 Latin America Neuroendocrine Carcinoma Market Size by Country
9.4.1 Latin America Neuroendocrine Carcinoma Market Size by Country (2016-2021)
9.4.2 Latin America Neuroendocrine Carcinoma Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuroendocrine Carcinoma Market Size (2016-2027)
10.2 Middle East & Africa Neuroendocrine Carcinoma Market Size by Type
10.2.1 Middle East & Africa Neuroendocrine Carcinoma Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neuroendocrine Carcinoma Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neuroendocrine Carcinoma Market Size by Type (2016-2027)
10.3 Middle East & Africa Neuroendocrine Carcinoma Market Size by Application
10.3.1 Middle East & Africa Neuroendocrine Carcinoma Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neuroendocrine Carcinoma Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neuroendocrine Carcinoma Market Size by Application (2016-2027)
10.4 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country
10.4.1 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Neuroendocrine Carcinoma Introduction
11.1.4 Pfizer Revenue in Neuroendocrine Carcinoma Business (2016-2021)
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Neuroendocrine Carcinoma Introduction
11.2.4 Novartis Revenue in Neuroendocrine Carcinoma Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 Chiasma
11.3.1 Chiasma Company Details
11.3.2 Chiasma Business Overview
11.3.3 Chiasma Neuroendocrine Carcinoma Introduction
11.3.4 Chiasma Revenue in Neuroendocrine Carcinoma Business (2016-2021)
11.3.5 Chiasma Recent Development
11.4 Ipsen
11.4.1 Ipsen Company Details
11.4.2 Ipsen Business Overview
11.4.3 Ipsen Neuroendocrine Carcinoma Introduction
11.4.4 Ipsen Revenue in Neuroendocrine Carcinoma Business (2016-2021)
11.4.5 Ipsen Recent Development
11.5 Abbvie
11.5.1 Abbvie Company Details
11.5.2 Abbvie Business Overview
11.5.3 Abbvie Neuroendocrine Carcinoma Introduction
11.5.4 Abbvie Revenue in Neuroendocrine Carcinoma Business (2016-2021)
11.5.5 Abbvie Recent Development
11.6 Valeant
11.6.1 Valeant Company Details
11.6.2 Valeant Business Overview
11.6.3 Valeant Neuroendocrine Carcinoma Introduction
11.6.4 Valeant Revenue in Neuroendocrine Carcinoma Business (2016-2021)
11.6.5 Valeant Recent Development
11.7 Jubilant
11.7.1 Jubilant Company Details
11.7.2 Jubilant Business Overview
11.7.3 Jubilant Neuroendocrine Carcinoma Introduction
11.7.4 Jubilant Revenue in Neuroendocrine Carcinoma Business (2016-2021)
11.7.5 Jubilant Recent Development
11.8 Teva
11.8.1 Teva Company Details
11.8.2 Teva Business Overview
11.8.3 Teva Neuroendocrine Carcinoma Introduction
11.8.4 Teva Revenue in Neuroendocrine Carcinoma Business (2016-2021)
11.8.5 Teva Recent Development
11.9 F.Hoffmann-La Roche
11.9.1 F.Hoffmann-La Roche Company Details
11.9.2 F.Hoffmann-La Roche Business Overview
11.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Introduction
11.9.4 F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2016-2021)
11.9.5 F.Hoffmann-La Roche Recent Development
11.10 Advanced Accelerator
11.10.1 Advanced Accelerator Company Details
11.10.2 Advanced Accelerator Business Overview
11.10.3 Advanced Accelerator Neuroendocrine Carcinoma Introduction
11.10.4 Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2016-2021)
11.10.5 Advanced Accelerator Recent Development
11.11 Mateon
11.11.1 Mateon Company Details
11.11.2 Mateon Business Overview
11.11.3 Mateon Neuroendocrine Carcinoma Introduction
11.11.4 Mateon Revenue in Neuroendocrine Carcinoma Business (2016-2021)
11.11.5 Mateon Recent Development
11.12 Lexicon
11.12.1 Lexicon Company Details
11.12.2 Lexicon Business Overview
11.12.3 Lexicon Neuroendocrine Carcinoma Introduction
11.12.4 Lexicon Revenue in Neuroendocrine Carcinoma Business (2016-2021)
11.12.5 Lexicon Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Neuroendocrine Carcinoma Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Somatostatin Analogs
Table 4. Key Players of Targeted Therapy
Table 5. Global Neuroendocrine Carcinoma Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Neuroendocrine Carcinoma Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Neuroendocrine Carcinoma Market Size by Regions (2016-2021) & (US$ Million)
Table 8. Global Neuroendocrine Carcinoma Market Share by Regions (2016-2021)
Table 9. Global Neuroendocrine Carcinoma Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 10. Global Neuroendocrine Carcinoma Market Share by Regions (2022-2027)
Table 11. Neuroendocrine Carcinoma Market Trends
Table 12. Neuroendocrine Carcinoma Market Drivers
Table 13. Neuroendocrine Carcinoma Market Challenges
Table 14. Neuroendocrine Carcinoma Market Restraints
Table 15. Global Neuroendocrine Carcinoma Revenue by Players (2016-2021) & (US$ Million)
Table 16. Global Neuroendocrine Carcinoma Market Share by Players (2016-2021)
Table 17. Global Top Neuroendocrine Carcinoma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma as of 2020)
Table 18. Ranking of Global Top Neuroendocrine Carcinoma Companies by Revenue (US$ Million) in 2020
Table 19. Global 5 Largest Players Market Share by Neuroendocrine Carcinoma Revenue (CR5 and HHI) & (2016-2021)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Neuroendocrine Carcinoma Product Solution and Service
Table 22. Date of Enter into Neuroendocrine Carcinoma Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Neuroendocrine Carcinoma Market Size by Type (2016-2021) (US$ Million)
Table 25. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2016-2021)
Table 26. Global Neuroendocrine Carcinoma Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 27. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 28. Global Neuroendocrine Carcinoma Market Size Share by Application (2016-2021) & (US$ Million)
Table 29. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2016-2021)
Table 30. Global Neuroendocrine Carcinoma Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 31. Global Neuroendocrine Carcinoma Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 32. North America Neuroendocrine Carcinoma Market Size by Type (2016-2021) (US$ Million)
Table 33. North America Neuroendocrine Carcinoma Market Size by Type (2022-2027) & (US$ Million)
Table 34. North America Neuroendocrine Carcinoma Market Size by Application (2016-2021) (US$ Million)
Table 35. North America Neuroendocrine Carcinoma Market Size by Application (2022-2027) & (US$ Million)
Table 36. North America Neuroendocrine Carcinoma Market Size by Country (2016-2021) & (US$ Million)
Table 37. North America Neuroendocrine Carcinoma Market Size by Country (2022-2027) & (US$ Million)
Table 38. Europe Neuroendocrine Carcinoma Market Size by Type (2016-2021) (US$ Million)
Table 39. Europe Neuroendocrine Carcinoma Market Size by Type (2022-2027) & (US$ Million)
Table 40. Europe Neuroendocrine Carcinoma Market Size by Application (2016-2021) (US$ Million)
Table 41. Europe Neuroendocrine Carcinoma Market Size by Application (2022-2027) & (US$ Million)
Table 42. Europe Neuroendocrine Carcinoma Market Size by Country (2016-2021) & (US$ Million)
Table 43. Europe Neuroendocrine Carcinoma Market Size by Country (2022-2027) & (US$ Million)
Table 44. Asia-Pacific Neuroendocrine Carcinoma Market Size by Type (2016-2021) (US$ Million)
Table 45. Asia-Pacific Neuroendocrine Carcinoma Market Size by Type (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Neuroendocrine Carcinoma Market Size by Application (2016-2021) (US$ Million)
Table 47. Asia-Pacific Neuroendocrine Carcinoma Market Size by Application (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2016-2021) & (US$ Million)
Table 49. Asia-Pacific Neuroendocrine Carcinoma Market Size by Region (2022-2027) & (US$ Million)
Table 50. Latin America Neuroendocrine Carcinoma Market Size by Type (2016-2021) (US$ Million)
Table 51. Latin America Neuroendocrine Carcinoma Market Size by Type (2022-2027) & (US$ Million)
Table 52. Latin America Neuroendocrine Carcinoma Market Size by Application (2016-2021) (US$ Million)
Table 53. Latin America Neuroendocrine Carcinoma Market Size by Application (2022-2027) & (US$ Million)
Table 54. Latin America Neuroendocrine Carcinoma Market Size by Country (2016-2021) & (US$ Million)
Table 55. Latin America Neuroendocrine Carcinoma Market Size by Country (2022-2027) & (US$ Million)
Table 56. Middle East & Africa Neuroendocrine Carcinoma Market Size by Type (2016-2021) (US$ Million)
Table 57. Middle East & Africa Neuroendocrine Carcinoma Market Size by Type (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Neuroendocrine Carcinoma Market Size by Application (2016-2021) (US$ Million)
Table 59. Middle East & Africa Neuroendocrine Carcinoma Market Size by Application (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2016-2021) & (US$ Million)
Table 61. Middle East & Africa Neuroendocrine Carcinoma Market Size by Country (2022-2027) & (US$ Million)
Table 62. Pfizer Company Details
Table 63. Pfizer Business Overview
Table 64. Pfizer Neuroendocrine Carcinoma Product
Table 65. Pfizer Revenue in Neuroendocrine Carcinoma Business (2016-2021) & (US$ Million)
Table 66. Pfizer Recent Development
Table 67. Novartis Company Details
Table 68. Novartis Business Overview
Table 69. Novartis Neuroendocrine Carcinoma Product
Table 70. Novartis Revenue in Neuroendocrine Carcinoma Business (2016-2021) & (US$ Million)
Table 71. Novartis Recent Development
Table 72. Chiasma Company Details
Table 73. Chiasma Business Overview
Table 74. Chiasma Neuroendocrine Carcinoma Product
Table 75. Chiasma Revenue in Neuroendocrine Carcinoma Business (2016-2021) & (US$ Million)
Table 76. Chiasma Recent Development
Table 77. Ipsen Company Details
Table 78. Ipsen Business Overview
Table 79. Ipsen Neuroendocrine Carcinoma Product
Table 80. Ipsen Revenue in Neuroendocrine Carcinoma Business (2016-2021) & (US$ Million)
Table 81. Ipsen Recent Development
Table 82. Abbvie Company Details
Table 83. Abbvie Business Overview
Table 84. Abbvie Neuroendocrine Carcinoma Product
Table 85. Abbvie Revenue in Neuroendocrine Carcinoma Business (2016-2021) & (US$ Million)
Table 86. Abbvie Recent Development
Table 87. Valeant Company Details
Table 88. Valeant Business Overview
Table 89. Valeant Neuroendocrine Carcinoma Product
Table 90. Valeant Revenue in Neuroendocrine Carcinoma Business (2016-2021) & (US$ Million)
Table 91. Valeant Recent Development
Table 92. Jubilant Company Details
Table 93. Jubilant Business Overview
Table 94. Jubilant Neuroendocrine Carcinoma Product
Table 95. Jubilant Revenue in Neuroendocrine Carcinoma Business (2016-2021) & (US$ Million)
Table 96. Jubilant Recent Development
Table 97. Teva Company Details
Table 98. Teva Business Overview
Table 99. Teva Revenue in Neuroendocrine Carcinoma Business (2016-2021) & (US$ Million)
Table 100. Teva Recent Development
Table 101. F.Hoffmann-La Roche Company Details
Table 102. F.Hoffmann-La Roche Business Overview
Table 103. F.Hoffmann-La Roche Neuroendocrine Carcinoma Product
Table 104. F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2016-2021) & (US$ Million)
Table 105. F.Hoffmann-La Roche Recent Development
Table 106. Advanced Accelerator Company Details
Table 107. Advanced Accelerator Business Overview
Table 108. Advanced Accelerator Neuroendocrine Carcinoma Product
Table 109. Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2016-2021) & (US$ Million)
Table 110. Advanced Accelerator Recent Development
Table 111. Mateon Company Details
Table 112. Mateon Business Overview
Table 113. Mateon Neuroendocrine Carcinoma Product
Table 114. Mateon Revenue in Neuroendocrine Carcinoma Business (2016-2021) & (US$ Million)
Table 115. Mateon Recent Development
Table 116. Lexicon Company Details
Table 117. Lexicon Business Overview
Table 118. Lexicon Neuroendocrine Carcinoma Product
Table 119. Lexicon Revenue in Neuroendocrine Carcinoma Business (2016-2021) & (US$ Million)
Table 120. Lexicon Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuroendocrine Carcinoma Market Share by Type: 2020 VS 2027
Figure 2. Chemotherapy Features
Figure 3. Somatostatin Analogs Features
Figure 4. Targeted Therapy Features
Figure 5. Global Neuroendocrine Carcinoma Market Share by Application: 2020 VS 2027
Figure 6. Hospital Case Studies
Figure 7. Clinics Case Studies
Figure 8. Oncology Centres Case Studies
Figure 9. Ambulatory Surgery Centres Case Studies
Figure 10. Neuroendocrine Carcinoma Report Years Considered
Figure 11. Global Neuroendocrine Carcinoma Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Neuroendocrine Carcinoma Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Neuroendocrine Carcinoma Market Share by Regions: 2020 VS 2027
Figure 14. Global Neuroendocrine Carcinoma Market Share by Regions (2022-2027)
Figure 15. Global Neuroendocrine Carcinoma Market Share by Players in 2020
Figure 16. Global Top Neuroendocrine Carcinoma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Neuroendocrine Carcinoma Revenue in 2020
Figure 18. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2016-2021)
Figure 19. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2022-2027)
Figure 20. North America Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Neuroendocrine Carcinoma Market Share by Type (2016-2027)
Figure 22. North America Neuroendocrine Carcinoma Market Share by Application (2016-2027)
Figure 23. North America Neuroendocrine Carcinoma Market Share by Country (2016-2027)
Figure 24. United States Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Neuroendocrine Carcinoma Market Share by Type (2016-2027)
Figure 28. Europe Neuroendocrine Carcinoma Market Share by Application (2016-2027)
Figure 29. Europe Neuroendocrine Carcinoma Market Share by Country (2016-2027)
Figure 30. Germany Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Neuroendocrine Carcinoma Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Neuroendocrine Carcinoma Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Neuroendocrine Carcinoma Market Share by Region (2016-2027)
Figure 40. China Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Neuroendocrine Carcinoma Market Share by Type (2016-2027)
Figure 48. Latin America Neuroendocrine Carcinoma Market Share by Application (2016-2027)
Figure 49. Latin America Neuroendocrine Carcinoma Market Share by Country (2016-2027)
Figure 50. Mexico Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Neuroendocrine Carcinoma Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Neuroendocrine Carcinoma Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Neuroendocrine Carcinoma Market Share by Country (2016-2027)
Figure 56. Turkey Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Neuroendocrine Carcinoma Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Pfizer Revenue Growth Rate in Neuroendocrine Carcinoma Business (2016-2021)
Figure 60. Novartis Revenue Growth Rate in Neuroendocrine Carcinoma Business (2016-2021)
Figure 61. Chiasma Revenue Growth Rate in Neuroendocrine Carcinoma Business (2016-2021)
Figure 62. Ipsen Revenue Growth Rate in Neuroendocrine Carcinoma Business (2016-2021)
Figure 63. Abbvie Revenue Growth Rate in Neuroendocrine Carcinoma Business (2016-2021)
Figure 64. Valeant Revenue Growth Rate in Neuroendocrine Carcinoma Business (2016-2021)
Figure 65. Jubilant Revenue Growth Rate in Neuroendocrine Carcinoma Business (2016-2021)
Figure 66. Teva Revenue Growth Rate in Neuroendocrine Carcinoma Business (2016-2021)
Figure 67. F.Hoffmann-La Roche Revenue Growth Rate in Neuroendocrine Carcinoma Business (2016-2021)
Figure 68. Advanced Accelerator Revenue Growth Rate in Neuroendocrine Carcinoma Business (2016-2021)
Figure 69. Mateon Revenue Growth Rate in Neuroendocrine Carcinoma Business (2016-2021)
Figure 70. Lexicon Revenue Growth Rate in Neuroendocrine Carcinoma Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
世界の神経内分泌機能検査市場規模・現状・予測（2021年-2027年） Neuroendocrine function test is a diagnosis process of finding out the neuroendocrine tumor. Based on treatment type, the global neuroendocrine function test market is segmented surgery and medication. As surgery is widely used in the neuroendocrine function test market. Similarly, based on end user…- 世界の外来手術センター市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Ambulatory Surgical Centres Market The global Ambulatory Surgical Centres market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity…
- 世界のメルケル細胞癌治療市場規模・現状・予測（2021年-2027年） Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine tumor of the skin. Market Analysis and Insights: Global Merkel Cell Carcinoma Therapeutics Market The global Merkel Cell Carcinoma Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, a…
- 世界のメルケル細胞癌治療市場規模・現状・予測（2021年-2027年） Merkel Cell Carcinoma, a skin malignancy, is caused by the uncontrolled development of Merkel cells in the skin. MCC was originally first described by Toker in 1972. The malady is to a great extent caused by Merkel Cell Polyomavirus (MCV) on parts of the skin in the head, neck and arms, generally oc…
- 世界の基底細胞がん治療市場規模・現状・予測（2021年-2027年） Basal cell carcinoma (BCC) is the most common type of skin cancer. It’s also the most commonly diagnosed cancer in the United States. Every year, millions of people learn that they have BCC. Basal cell carcinoma that is superficial and doesn't extend very far into the skin may be treated with creams…